How to take Imdelltra (Tarlatamab-dlle)

Before administering Imdelltra (Tarlatamab-dlle), ensure that the patient is adequately hydrated. Assess complete blood count, liver enzymes, and bilirubin before each dose as clinically indicated. Imdelltrashould be used only by medical professionals with appropriate medical support to control serious reactions such asCRS and neurotoxicity, including immune effector cell-associated neurotoxic syndrome (ICANS), and patients should be monitored for 22 to 24 hours on Cycle 1 Day 1 and Cycle 1 Day 8; within 1 hour of starting the infusion and in an appropriate health care setting for a total of 48 hours.

1. Medication dosage: Imdelltra treatment plan is usually a 28-day (4-week) long cycle, adopting the recommended ascending dose plan, and using recommended combined medications. Give Imdelltra intravenously over one hour to reduce the incidence and severity of CRS.

(1) incremental plan:

1) Receive a smaller dose of Imdelltra, 1 mg, on Day 1 of the first treatment cycle (Cycle 1); receive the full treatment dose, 10 mg, on Days 8 and 15. On days 1 and 8, intravenously inject 8 mg of dexamethasone (or equivalent) within 1 hour before treatment with Imdelltra; on days 1, 8, and 15, inject 1 liter of normal saline intravenously within 4-5 hours immediately after completion of Imdelltrainfusion.

2) Receive the full treatment dose, i.e. 10mg, on day 1 and day 15 of the second treatment cycle (cycle 2);

3) Receive the full treatment dose, i.e. 10 mg, on day 1 and day 15 of the third and fourth treatment cycles (cycle 3);

4) Receive the full therapeutic dose, i.e. 10 mg, on days 1 and 15 of the fifth cycle and subsequent infusions;

(2) Imdelltra is administered every two weeks following an escalating dose regimen until disease progression or unacceptable toxicity.

2. Dosage adjustment: It is not recommended to reduce the dose of Imdelltra , but if adverse reactions occur after using the drug, it should be adjusted under the guidance of a doctor. Imdelltra treatment may be temporarily stopped or completely stopped if CRS, neurological problems, or any other serious side effects occur.